Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. - Wikidata - wikimedia - TriplyDB

Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies.

Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies.

http://www.wikidata.org/entity/Q38364464

about

Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.Pharmacokinetic modeling of therapies for systemic lupus erythematosus.Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease.Drug Development of Therapeutic Monoclonal Antibodies.Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus.Learning Health Systems as Facilitators of Precision Medicine.Individualized Infliximab Treatment Guided by Patient-managed eHealth in Children and Adolescents with Inflammatory Bowel Disease.Clinical performance of an infliximab rapid quantification assay.Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration.Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions.

P2860

Q38527434-4F7C06A1-99BD-4997-911F-90F1E36AB4B9 Q38542910-3BA057A8-685B-48A1-BD41-9E42FD006A6E Q38548889-84B90DDA-0309-489A-8163-B01399A3B135 Q38822920-4BDBB997-3607-4BB7-8E9C-C3C59C2A7C32 Q38850063-18C6D973-566B-4629-8C14-91B7370153A9 Q38876360-438693D9-5D2D-424B-9609-82BEE39DDA09 Q38888137-84D64C6F-3AC1-408E-BC95-D8488C983078 Q39041482-848266DD-18B3-4853-8445-865EFCA50905 Q40159033-3645DBD3-7009-41E3-A957-798A826DE2EA Q41078459-A2EF7BB2-02F0-40F2-8C71-8A8230155F57 Q41078498-724DF385-CB5D-41E5-B27B-221D755A3392 Q47194271-719D4D22-8BFC-4B2B-B8C8-96F88037D112 Q49171317-CB741D25-3916-406C-A5EB-A93E15A9E5D8 Q53523796-BB514FBA-7B72-41CC-AA73-E3EE1490A8F2 Q55258447-87075CBD-EE48-4695-9298-C8D4BBBCA87C

P2860

Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies.

http://www.wikidata.org/entity/Q38364464

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Dashboard systems: Pharmacokin ...... ion for monoclonal antibodies.

@en

type

label

Dashboard systems: Pharmacokin ...... ion for monoclonal antibodies.

@en

prefLabel

Dashboard systems: Pharmacokin ...... ion for monoclonal antibodies.

@en

P1433

Q38364464-83F24C71-5AA0-49A4-9E9D-DF2DA5CD51CC

P1476

Q38364464-063C0345-33A8-4B7E-8692-6B6129C178DB

P2093

Q38364464-5E7A6B85-AE73-4E09-BBBA-2E9B30A06F91

Q38364464-8A37654D-8D7F-48F8-BD3E-D0122E2A43D8

P2860

Q38364464-028E34F0-901B-40AF-B34E-91CA73E84643

Q38364464-08AAA01B-3AB6-47BB-B91F-0FC98D41777E

Q38364464-08C66D2F-B05A-420E-9825-BAADDF9C9B0F

Q38364464-19C4C768-9F48-4004-8A4D-16471E40FE39

Q38364464-1A342DD5-5EC7-4892-8D5F-53EADFBF33E2

Q38364464-1F59D833-1FB3-4B57-947C-FD2A0F7D9DD2

Q38364464-299C1751-82FB-4399-AE40-D779E807A9B8

Q38364464-2E748606-99D1-44FA-9F92-A8AEAB13CDC2

Q38364464-33E781D0-21A7-4270-9933-8FB8316D4F77

Q38364464-35D3D631-C99E-4DAD-9683-7977F4A5F1F0

P304

Q38364464-FACD7517-0FC3-4225-BC32-4DC2DDDFDFF2

P31

Q38364464-FE1EFB1E-A314-4530-A16E-A53E4C9FCF3F

P356

Q38364464-E1143B32-48F5-49BF-9F6A-93C3D90A01C5

P478

Q38364464-5D162DB6-0B7B-49AA-8662-DDAA6BDFA028

P577

Q38364464-559B2E7F-8904-4C5A-B7F2-178C0FCC9487

P5875

Q38364464-B91335F4-00E4-4350-923E-2E81D67F9922

P698

Q38364464-499F7226-999E-4F66-8855-8DA708F89DA5

P356

P1433

The Journal of Clinical Pharmacology

P1476

Dashboard systems: Pharmacokin ...... ion for monoclonal antibodies.

@en

P2093

Diane R Mould

http://www.w3.org/2001/XMLSchema#string

Marla C Dubinsky

http://www.w3.org/2001/XMLSchema#string

P2860

MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells

Forecasting individual pharmacokinetics

Inflammatory bowel disease: cause and immunobiology.

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

Lymphatic transport of proteins after subcutaneous administration.

Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease

Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies.

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

P304

S51-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.370

http://www.w3.org/2001/XMLSchema#string

P478

55 Suppl 3

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272844219

http://www.w3.org/2001/XMLSchema#string

P698

25707964

http://www.w3.org/2001/XMLSchema#string